Ceesay Abraham sold $938K of RAPP
Ceesay Abraham (Chief Executive Officer) sold 18,921 shares of Rapport Therapeutics, Inc. (RAPP) at $49.57 ($0.94M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, providing new data for traders.
Market read
While the filing is a primary source, the modest size limits its trading relevance.
What to watch
The CEO's remaining stake remains sizable, and the 10b5-1 plan suggests pre‑planned execution.
Background
Form 4 filings disclose insider transactions; investors monitor them for signals of insider confidence.
Ticker impact
CEO Ceesay Abraham sold 18,921 shares for $938K via a 10b5-1 plan, reducing his stake to 467,187 shares.
Potential slight downward pressure in the near term, likely within a few cents.
A sub‑$1M sale by the CEO is disclosed for the first time, but the scale is modest and unlikely to move the stock dramatically.
Market effects
Minimal impact on the biotech sector; insider sales are routine.
No regional effect beyond the company's own share price.
Limited global relevance.
Counterpoint
The sale could be a routine liquidity event rather than a lack of confidence.
Key entities
- CompanyRapport Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker RAPP.
- ExecutiveCeesay Abraham
Chief Executive Officer of Rapport Therapeutics.